Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Appointment

9 Nov 2007 16:59

Avacta Group plc Board Appointment

Avacta Group plc ("Avacta" or the "Company"), which develops detection and analysis technology aimed at the biopharmaceutical, defence & security and clinical diagnostics markets, is pleased to announce the appointment of Russell Hodgetts to the Board of Directors, with effect from 10 July 2007.

Russell Winston Hodgetts, 36, has been Chief Operating Officer of Avacta since October 2005, and has a wealth of experience in strategic business development and group operations. Prior to joining Avacta he worked for Techtran Group Limited where he helped guide the commercialization and business development of companies created from University of Leeds research and intellectual property.

He currently oversees the development of the analytical services division of the Company in addition to being responsible for group operations.

Russell Hodgetts is the beneficial owner of 9,847,912 ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares"), representing approximately 1.27 per cent. of the issued share capital of the Company and 1,804,568 options to acquire Ordinary Shares at an exercise price of 2.25p per share.

He is also a director of Avacta Analytical Limited.

Russell Hodgetts was named Russell Beckett until family circumstances led to his name being changed when aged 11.

There are no other disclosures required by paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Professor Alastair Smith, Chief Executive, Avacta Group plc, commented:

"Russell has been an integral part of the development of Avacta over the past two years and his focus on continued growth has been central to the success of Avacta Analytical Ltd. We are pleased to welcome him to the Board and will continue to draw on his knowledge and drive to ensure that Avacta maintains its current path of development and innovation."

9 November 2007EnquiriesAvacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Limited Tel: 020 7562 4713 Henry Turcan/Michael Brennan Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk

AVACTA GROUP PLC
Date   Source Headline
22nd Apr 20209:05 amRNSSecond Price Monitoring Extn
22nd Apr 20209:00 amRNSPrice Monitoring Extension
22nd Apr 20207:00 amRNSAvacta/Cytiva Partnership Ahead of Schedule
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
17th Apr 20207:00 amRNSNotice of Results - Update
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:36 pmRNSPrice Monitoring Extension
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20209:05 amRNSSecond Price Monitoring Extn
15th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20205:30 pmRNSHolding(s) in Company
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
14th Apr 202011:05 amRNSSecond Price Monitoring Extn
14th Apr 202011:00 amRNSPrice Monitoring Extension
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:37 pmRNSPrice Monitoring Extension
8th Apr 20202:05 pmRNSSecond Price Monitoring Extn
8th Apr 20202:00 pmRNSPrice Monitoring Extension
8th Apr 202011:05 amRNSSecond Price Monitoring Extn
8th Apr 202011:00 amRNSPrice Monitoring Extension
8th Apr 20209:05 amRNSSecond Price Monitoring Extn
8th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSAvacta & Cytiva Collaborate on COVID-19 Rapid Test
6th Apr 20205:45 pmRNSHolding(s) in Company
6th Apr 20202:06 pmRNSSecond Price Monitoring Extn
6th Apr 20202:01 pmRNSPrice Monitoring Extension
6th Apr 20207:00 amRNSProposed Placing to raise £3.75 million
2nd Apr 20207:01 amRNSAppointment of Joint Broker
2nd Apr 20207:00 amRNSSubscription to raise £2 million
26th Mar 202011:05 amRNSSecond Price Monitoring Extn
26th Mar 202011:00 amRNSPrice Monitoring Extension
24th Mar 20202:06 pmRNSSecond Price Monitoring Extn
24th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20204:42 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
10th Mar 20207:00 amRNSShareholder/Investor Meeting and Presentation
13th Feb 20207:00 amRNSNotice of Results
11th Feb 20207:00 amRNSShare Incentive Plan/Issue of Equity
3rd Feb 20207:00 amRNSAvacta and Daewoong Agreement
29th Jan 20202:45 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSSuccessful initial proof-of-concept
23rd Jan 20207:00 amRNSTrading Update
21st Jan 20207:00 amRNSDirector Appointment
8th Jan 20207:00 amRNSAvacta and Daewoong Establish Joint Venture
26th Nov 20199:00 amRNSHolding(s) in Company
22nd Nov 20198:41 amRNSDirector/PDMR Shareholding
13th Nov 20197:00 amRNSLG Chem Life Sciences Expands Partnership

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.